Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$6.04 -5.6%	$5.83	$3.79 ▼ $14.60	$320.66M	-0.88	708,692 shs	1.13 million shs
CMPX Compass Therapeutics	$2.95 -4.8%	$2.79	$1.15 ▼ $4.08	$428.68M	1.49	1.21 million shs	2.04 million shs
IMMP Prima BioMed	$1.72 -0.6%	$1.70	$1.32 ▼ $2.72	$253.94M	1.66	77,517 shs	28,701 shs
JMAC Maxpro Capital Acquisition	$5.80 +0.3%	$6.15	$7.50 ▼ $19.22	$77.88M	0.01	74,040 shs	43,353 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	-5.63%	+3.42%	-3.36%	+12.90%	+14.83%
CMPX Compass Therapeutics	-4.84%	+6.12%	-1.01%	+40.48%	+158.77%
IMMP Prima BioMed	-0.58%	-4.97%	+5.52%	-15.27%	-20.37%
JMAC Maxpro Capital Acquisition	+1.93%	+4.13%	+1.05%	+18.13%	+4,028.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CADL Candel Therapeutics	2.7682 of 5 stars	3.6	2.0	0.0	0.0	3.2	1.7	0.6
CMPX Compass Therapeutics	2.7311 of 5 stars	3.6	1.0	0.0	0.0	2.2	5.0	0.0
IMMP Prima BioMed	1.4564 of 5 stars	3.5	1.0	0.0	0.0	2.7	0.0	0.0
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	3.20	Buy	$22.00	264.24% Upside
CMPX Compass Therapeutics	3.10	Buy	$12.89	336.91% Upside
IMMP Prima BioMed	3.00	Buy	$7.00	306.98% Upside
JMAC Maxpro Capital Acquisition	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest JMAC, CMPX, IMMP, and CADL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
8/12/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
7/9/2025	CADL Candel Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00
6/30/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$23.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	$120K	2,521.70	N/A	N/A	$1.41 per share	4.28
CMPX Compass Therapeutics	$850K	479.91	N/A	N/A	$0.67 per share	4.40
IMMP Prima BioMed	$5.14M	49.12	N/A	N/A	$1.05 per share	1.64
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$55.18M	-$1.34	N/A	N/A	N/A	N/A	-136.74%	-63.13%	N/A
CMPX Compass Therapeutics	-$49.38M	-$0.45	N/A	N/A	N/A	N/A	-53.11%	-46.14%	N/A
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/29/2025 (Estimated)
JMAC Maxpro Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest JMAC, CMPX, IMMP, and CADL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	CADL Candel Therapeutics	-$0.17	-$0.09	+$0.08	-$0.09	N/A	N/A
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	-$0.14	-$0.01	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.01	4.64	4.64
CMPX Compass Therapeutics	N/A	7.66	8.33
IMMP Prima BioMed	N/A	18.86	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
CMPX Compass Therapeutics	68.43%
IMMP Prima BioMed	2.32%
JMAC Maxpro Capital Acquisition	73.18%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	16.60%
CMPX Compass Therapeutics	29.80%
IMMP Prima BioMed	3.07%
JMAC Maxpro Capital Acquisition	19.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	50.10 million	41.79 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
IMMP Prima BioMed	2,021	146.79 million	142.28 million	Optionable
JMAC Maxpro Capital Acquisition	2,021	13.43 million	10.84 million	Not Optionable

JMAC, CMPX, IMMP, and CADL Headlines

Recent News About These Companies

Maxpro Capital Acquisition (NASDAQ:JMAC) Trading Up 1.2% - Time to Buy?

August 3, 2025 | marketbeat.com

Denali Capital Acquisition Corp Ordinary Shares - Class A

May 23, 2024 | morningstar.comM

Denali Capital Acquisition Corp Ordinary Shares - Class A DECA Stock Quote

July 21, 2023 | morningstar.comM

Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq

June 6, 2023 | finance.yahoo.com

Maxpro Capital Acquisition Corp

April 5, 2022 | reuters.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JMAC, CMPX, IMMP, and CADL Company Descriptions

Candel Therapeutics NASDAQ:CADL

$6.04 -0.36 (-5.63%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$6.09 +0.05 (+0.83%)

As of 08/14/2025 07:56 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Compass Therapeutics NASDAQ:CMPX

$2.95 -0.15 (-4.84%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$3.00 +0.05 (+1.69%)

As of 08/14/2025 06:57 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Prima BioMed NASDAQ:IMMP

$1.72 -0.01 (-0.58%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.69 -0.03 (-1.74%)

As of 08/14/2025 07:32 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Maxpro Capital Acquisition NASDAQ:JMAC

$5.80 +0.02 (+0.35%)

As of 08/13/2025

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time